AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback.

RecruitingNAAges 18 Years - anyAllHospital Clinic of Barcelona
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is designed to compare two surgical techniques used to create arteriovenous fistulas (AVFs), which are necessary for hemodialysis in patients with advanced chronic kidney disease (CKD). AVFs are preferred over other forms of vascular access because they last longer and have fewer complications. However, many AVFs fail to mature properly, making them unusable for dialysis. The two techniques being studied are the traditional End-to-Side (ETS) method and a newer technique called Piggyback Straight Line Onlay Technique (pSLOT). Early studies suggest that pSLOT may reduce complications like narrowing (stenosis), clotting (thrombosis), and failure of the AVF, but more robust data from randomized clinical trials is needed. Patients aged 18 or older with stage 4 or 5 CKD, who are eligible for a new AVF and meet health criteria, may participate. During the operation, participants ar

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age \> 18 years * Able to meet protocol requirements, including follow-up. * Incident or prevalent patient with advanced chronic kidney disease in the hemodialysis stage (stage 5D). * In predialysis patients (stage 5), if renal replacement therapy (hemodialysis) is anticipated to be required within the next 6 months (based on standard clinical criteria). * Who, based on their associated pathology and according to medical criteria, can withstand the initial surgery and arteriovenous access maintenance procedures. * Have a current ultrasound with preoperative venous and arterial mapping. * Meet the anatomical requirements for AVF creation: * Wrist: artery \>2 mm, vein \>2 mm in diameter * Elbow: artery \>3 mm, vein \>3 mm in diameter * Absence of arterial calcification or occlusion, or other aberrant arterial anatomy. * Adequate arterial and venous patency. * Vein-to-skin distance \<5 mm. * Candidate for creation of a native arteriovenous fistula for hemodialysis, either distal (radiocephalic) or proximal (humerocephalic or humerobasilic). * No immediate transplant scheduled within the next 60 days (inclusion on the kidney transplant waiting list is not a contraindication for entry into the study, nor for the creation of an arteriovenous fistula). * No prior arteriovenous surgeries in the same or proximal location. * Correct understanding of the study conditions and acceptance to participate. Exclusion Criteria: * Pregnant women. * Life expectancy \<1 year. * Arteriovenous prostheses (non-native fistulas), previous arteriovenous fistula repairs, arteriovenous accesses created in the lower extremities, and unusual (exotic) accesses. * Known or suspected central venous stenosis/occlusion on the side of the planned access. * Repair of previous arteriovenous accesses (proximal reanastomoses). * Biological immunosuppression. * History or evidence of serious systemic illness, including: * Cardiac disease (New York Heart Association functional class III or IV, as evidenced by the inability to lie still), myocardial infarction within 6 weeks prior to randomization, ventricular tachyarrhythmia requiring ongoing treatment, or unstable angina. Suspected or documented hypercoagulable or hypocoagulable state or Clinically significant active infection (White blood count \> 15,000 cells/mm3) other than the use of a treated CVC. * Any other condition that, in the investigator's judgment, prevents an adequate evaluation of the safety and efficacy of the study or poor compliance. * Patient unwilling or unable to attend follow-up follow-ups.
๐Ÿ’Š

What it tests

  • Terminolateral anastomotic technique
  • Piggyback anastomotic technique
๐Ÿ“

Where

1 site
Hospital Clรญnic de Barcelona
Barcelona, Spain
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy